According to the press release from Novo, U.S Food and Drug Administration have approved a new type 2 diabetes drug names liraglutide (Victoria, Novo Nordisk) which is indicated to reduce the risk of cardiovascular events in adults.
The approved indication is purely based on the clinical trial results. The clinical trial results demonstrated that Victoza reduces the risk of cardiovascular death and non-fatal stroke by 13% compared to the placebo.
The clinical trial study includes around 9340 participants to investigate the long-term efficacy of a drug when compared to a placebo. It is tested in individuals with type 2 diabetes at a high risk of cardiovascular events. The standard care during the trial includes certain lifestyle modifications, glucose-lowering treatments and cardiovascular medications.
This type-2 diabetic drug, Victoza received approval from FDA as an adjunct to diet and exercise to improve blood sugar control in adults. This improvised indication allows Victoza to be used to reduce the risk of major cardiovascular events like myocardial infarction and non-fatal stroke.
Victoza is the only type 2 diabetes treatment indication that is indicated to reduce the risk of major cardiovascular events. Victoza is a human glucagon-like peptide-1 (GLP-1) analogue with an amino acid sequence which is 97% similar to endogenous human GLP-1. Victoza was commercially available in more than 95 countries and is used to treat more than 1 million people with type 2 diabetes globally after it was approved in the EU in 2009.
In the US Victoza received approval in 2010 as an adjunct to diet and exercise to improve blood glucose control in adults suffering from type 2 diabetes. Now Vicotaza is approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes.